Search

everythinglearnresearchcommunity

for

Search:↓

Androstanediol glucuronide is a reliable marker for hirsutism in women.

Women with hyperandrogenism have higher androgen levels and lower SHBG, which may contribute to conditions like excessive hair growth and early puberty.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

Hair loss in men and women is linked to high stress hormone levels and other hormonal imbalances, suggesting treatments should be customized to each person's hormones.

Men with male pattern hair loss have different levels of certain hormones compared to men without hair loss.

Creating stronger blockers for skin enzymes might lead to better treatment for conditions like acne and excessive hair growth.

Androgens like testosterone are important hormones for both men and women, made differently in each sex and affecting the body by regulating genes and quick interactions with cell components.

Dihydrotestosterone (DHT) is crucial for conditions like male-pattern baldness and acne, and measuring a byproduct, androstanediol glucuronide, is a better way to assess DHT's effects than DHT blood levels.

The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.

People with hair loss may have different levels of certain hormones due to changes in hormone processing.

Women with female pattern hair loss have higher levels of certain androgens, suggesting increased androgen exposure to hair follicles.

Sebocytes play a key role in controlling androgen levels in human skin.

Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.

Men with male-pattern baldness have higher levels of certain testosterone metabolites and may have more active androgen metabolism.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Women with hair loss have higher androgen levels, while men with early balding have altered androgen ratios.

3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.

The document concludes that combination therapy is most effective for treating excessive hair growth in women with idiopathic hirsutism, and more research is needed to understand the condition.

Hirsutism is excessive male-pattern hair growth in women, often caused by hormonal imbalances, and requires ongoing treatment to manage.

Hair follicles are hormone-sensitive and involved in growth and other functions, with potential for new treatments, but more research is needed.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

The exact cause of increased 5α-reductase activity leading to hirsutism in women is still unknown.

Finasteride and spironolactone both reduce hirsutism, but finasteride lowers androgen levels more.

The document concludes that accurate measurement of serum androgens is crucial for diagnosing hyperandrogenism.

Finasteride safely lowers DHT levels without affecting testosterone.

Hormone treatments in transsexual individuals reduce hair growth and oil production in male-to-females and increase them in female-to-males.

New compounds may soon be tested to treat excessive hair growth in women.

The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.

Isotretinoin improves severe acne without changing androgen or insulin levels but may increase body weight and triglycerides.

Hormonal therapies are effective for managing hair and skin symptoms in women with PCOS.